Results of Nationwide Breast Cancer Prevention Trial Show Osteoporosis Drug Raloxifene is as Effective as Tamoxifen in Preventing Invasive Breast Cancer; Vanderbilt-Ingram Cancer Center is Only Regional Participant
Apr. 17, 2006—Initial Results of the Study of Tamoxifen and Raloxifene or STAR, released today revealed the osteoporosis drug raloxifene has been proved to be as effective as tamoxifen in preventing invasive breast cancer.
Vanderbilt-Ingram Cancer Center Research Earns Funding from Lance Armstrong Foundation to Study Effects of Exercise on Curbing Memory Problems Associated with Chemotherapy
Mar. 20, 2006—Researchers at the Vanderbilt-Ingram Cancer Center are studying whether exercise can help curb memory and cognitive problems experienced by many cancer survivors following chemotherapy.
Mar. 15, 2006—Ginseng, one of the most widely used herbs in traditional Chinese medicine, may improve survival and quality of life after a diagnosis of breast cancer, according to a recent study by Vanderbilt-Ingram Cancer Center researchers. The large epidemiological study, led by Xiao-Ou Shu, M.D., Ph.D., was published online recently in the American Journal of Epidemiology.
Vanderbilt-Ingram Cancer Center Receives Funding to Identify Signals for Breast Cancer in the Blood and Women at High-Risk for the Disease
Mar. 8, 2006—A team of researchers at Vanderbilt-Ingram Cancer Center has been awarded $1.5 million from the Susan G. Komen Breast Cancer Foundation.
Vanderbilt-Ingram Cancer Center Researcher Studies Effects of Cancer Treatment among Children of Survivors
Feb. 16, 2006—Can the high doses of chemotherapy and radiation that young cancer patients receive cause inherited health problems for their children?
Jan. 27, 2006—Thanks to Vanderbilt-Ingram Cancer Center's new Clinical Trials Mentor Program, patients considering enrolling in a clinical trial can now ask questions and get first-hand accounts from patient advocates who have already gone through the process.
Researchers at Vanderbilt-Ingram Cancer Center to conduct Phase II studies for the National Cancer Institute
Jan. 25, 2006—The Vanderbilt-Ingram Cancer Center has been chosen by the National Cancer Institute to join an elite group of researchers asked to test the most cutting-edge cancer treatments in Phase II clinical trials in both solid tumor and hematologic malignancies.
Jan. 10, 2006—Researchers at the Vanderbilt-Ingram Cancer Center have uncovered a clue to explain the invasive nature of an aggressive kind of brain tumor called glioblastoma multiforme, or gliomas, and their findings are published in this week's online edition of the journal Oncogene.
Nov. 28, 2005—The Vanderbilt-Ingram Cancer Center is leading a multi-institutional effort supported by the National Cancer Institute (NCI) to identify "molecular signatures" of lung cancer.
Nov. 2, 2005—The U.S. Food and Drug Administration has approved the first new therapy in almost a decade for pancreas cancer, the fourth leading cause of cancer death in the United States.
Oct. 7, 2005—When a woman is diagnosed with breast cancer, multiple clinic visits may begin to mount, along with questions that the patient wants answered sooner rather than later.